Vaccine (Recombinant protein vaccine) · Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides · developed by Vaxcyte
24-Valent Pneumococcal Conjugate Vaccine (VAX-24) is a vaccine given as a 0.5 mL intramuscular injection into the deltoid muscle. It is studied for prevention of pneumococcal disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05297578 | Phase 2 | Pneumococcal Vaccines | Completed | PCVX |
| NCT05266456 | Phase 1/2 | Pneumococcal Vaccines | Completed | PCVX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pneumococcal Vaccines
Updated Oct 25, 2026. Something wrong or missing? Report it on the PCVX page.
See PCVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PCVX catalysts and pipeline →